Sacituzumab Earns Regular FDA Approval for TNBC - NCI
By A Mystery Man Writer
Description
Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.researchgate.net/publication/279065174/figure/fig2/AS:601785601380357@1520488276633/Therapeutic-efficacy-of-IMMU-132-with-different-DARs-NCI-N87-human-gastric-carcinoma.png)
Therapeutic efficacy of IMMU-132 with different DARs. NCI-N87
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.researchgate.net/publication/371953176/figure/fig1/AS:11431281189858656@1695176972445/Overview-of-current-therapeutic-strategies-for-triple-negative-breast-cancer-Current-and_Q320.jpg)
PDF) Exploiting Therapeutic Vulnerabilities in Triple-Negative
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.cancer.gov/sites/g/files/xnrzdm211/files/styles/cgov_article/public/cgov_image/media_image/2021-05/BreastCancer_V7.jpg?h=c5cfb224&itok=6PAv_mJ9)
Sacituzumab Earns Regular FDA Approval for TNBC - NCI
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.biochempeg.com/usr/uploads/3/202007/TRODELVY-structure.jpg)
FDA Approves Sacituzumab Govitecan for Triple-Negative Breast
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.aacr.org/wp-content/uploads/2020/04/sacituzumab-tripneg-breast-cancer-SOURCE-600x450-1.jpg)
Targeting Triple-negative Breast Cancer
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.researchgate.net/publication/371666222/figure/fig1/AS:11431281189858660@1695176972663/Representative-treatment-algorithm-for-metastatic-TNBC-based-on-current-phase-III_Q320.jpg)
PDF) Metastatic Triple-Negative Breast Cancer
View of Sacituzumab Govitecan (Trodelvy) Canadian Journal of Health Technologies
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.oncoamericas.com/wp-content/uploads/2020/05/OncoAmericas_Banner_Site_Noticias_Triple-negative_Ingles_1200x628px.png)
FDA grants accelerated approval to sacituzumab govitecan-hziy for
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01796/article_deploy/html/images/pharmaceutics-15-01796-g002.png?1687506831)
Pharmaceutics, Free Full-Text
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://franticshanti.files.wordpress.com/2022/08/pembrolizumab-factoid.jpg?w=970)
Life Expectancy – Frantic Shanti
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.jhoponline.com/images/supplements/2022/TLG2245/table.png)
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.cell.com/cms/attachment/26e4fb1e-70db-41f7-a4ad-9e0f49599a1a/fx1_lrg.jpg)
Sacituzumab Earns Regular FDA Approval For TNBC NCI
![Sacituzumab Earns Regular FDA Approval for TNBC - NCI](https://www.sec.gov/Archives/edgar/data/1817713/000095017023007311/img110723401_25.jpg)
10-K
from
per adult (price varies by group size)